十四烷基硫酸钠(Sodium Tetradecyl Sulfate)

概要

基本信息

药物类型

小分子化药

别名

7-Ethyl-2-methyl-4-undecanol sulfate sodium salt、7-ethyl-2-methyl-4-undecanolsulfate, sodium salt、STS

+ [13]

靶点-

作用方式-

作用机制-

治疗领域

心血管疾病消化系统疾病

在研适应症-

非在研适应症

消化性溃疡静脉曲张

原研机构

Elkins-Sinn, Inc.

在研机构-

非在研机构

Elkins-Sinn, Inc.

权益机构-

最高研发阶段撤市

首次获批日期

美国 (1946-08-13),

消化性溃疡静脉曲张

最高研发阶段(中国)-

特殊审评孤儿药 (美国)

登录后查看时间轴

结构/序列

分子式C14H30NaO4S

InChIKeyZNVVFVQLSXWPEV-UHFFFAOYSA-N

CAS号139-88-8

关联

15

项与十四烷基硫酸钠相关的临床试验

CTRI/2023/12/060776

/ Not yet recruiting临床4期IIT

Evaluation of foam sclerotherapy with sodium tetradecyl sulphate in periorbital dermoid cysts - NIL

开始日期2023-12-26

申办/合作机构-

CTRI/2023/08/056023

/ Not yet recruiting临床2期IIT

EVALUATION OF EFFICACY OF 3% SODIUM TETRADECYL SULPHATE AND 25% DEXTROSE IN THE TREATMENT OF TEMPOROMANDIBULAR JOINT HYPERMOBILITY -A DOUBLE BLINDED -RANDOMISED CLINICAL TRIAL - NIL

开始日期2023-08-24

申办/合作机构-

NCT05597995

/ Unknown status临床2期IIT

A Prospective Clinical Trial Evaluating the Efficacy of 1.5% Sodium Tetradecyl Sulfate Foam Injection for the Treatment of Epidermoid Cysts

The objective of this study is to determine the efficacy, safety, tolerability, and patient satisfaction associated with the treatment of epidermoid cysts with injected 1.5% sodium tetradecyl sulfate (STS) foam.

开始日期2022-11-01

申办/合作机构-

100 项与十四烷基硫酸钠相关的临床结果

登录后查看更多信息

100 项与十四烷基硫酸钠相关的转化医学

登录后查看更多信息

100 项与十四烷基硫酸钠相关的专利（医药）

登录后查看更多信息

581

项与十四烷基硫酸钠相关的文献（医药）

2025-07-01·Journal of Vascular Surgery: Venous and Lymphatic Disorders

Ultrasound-guided foam sclerotherapy of the saphenous trunks is associated with a low 5-year recurrence rate and improved quality of life in patients with chronic venous disease: A multicenter study

Article

作者: Massaroni, Rosaria ; Andreucci, Eleonora ; Sozio, Giampaolo ; Carbone, Ludovico ; Mariani, Fabrizio ; Bianchi, Valerio ; Bucalossi, Matteo

OBJECTIVEThe study attempts to test whether ultrasound-guided foam sclerotherapy (UGFS) is a durable treatment for incompetent great saphenous vein (GSV) and incompetent small saphenous vein (SSV) in primary chronic venous disease (CVD), Clinical-Etiology-Anatomy-Pathophysiology (CEAP) clinical grade 2 to 4 disease. Secondary end points are to evaluate its safety in terms of complications, to compare patients' quality of life before and after the treatment, and to identify risk factors that may predict recurrence of CVD after UGFS.METHODSMulticenter retrospective cohort study on 346 patients. The sclerosing agent was sodium tetradecyl sulfate (STS) in foam. The foam was prepared with the double-syringe technique (liquid-to-gas CO₂O_{2 30:70} ratio of 1:4). The sclerosing agent concentrations were 1% for saphenous trunk diameter 4 to 7 mm, 3% for saphenous trunk of >7 mm. Sodium tetradecyl sulfate was injected directly into the GSV/SSV, achieving a total maximum volume of 10 mL per session. A median of two sessions was performed (range, 1-5).RESULTSIn this cohort, 205 patients were categorized as CEAP C2 (59.2%), and 141 (40.8%) had worse CVD (CEAP ≥3). The median follow-up was 60 months (range, 6-60 months). At the end of follow-up, 296 patients (85.5%) had no truncal reflux, with a 5-year disease-free time (between last procedure and evidence of recurrent disease) of 77.7 ± 2.16%. GSV and SSV showed similar 5-year recurrence-free time rates (69.9% vs 76.8%; P = ns), whereas patients with a diameter of the saphenous trunk of ≤8 mm had lower recurrence than those with >8 mm (91.3% vs 46%; P < .0001). Ninety patients (26%) showed CVD recurrence, occurring at a median of 48 months. A further UGFS treatment was needed in 50 symptomatic patients (14.4%), resulting in an 80% success rate. At univariate analysis, large diameter of the saphenous trunk (P < .0001), male sex (P = .030) and greater number of treatment sessions (P = .009) were identified as significant prognostic factors for recurrence. Immediate complications occurred in 3.7% of patients: seven headache and six visual disturbances. Endovenous foam-induced thrombosis was detected in six patients (2.8%) 1 week after treatment. Cutaneous hyperpigmentation appeared in 37 patients (10.7%). Post-treatment revised Venous Clinical Severity Score and Chronic Venous Disease Quality of Life Questionnaire 14 scores were significantly lower than before treatment (P < .001).CONCLUSIONSUGFS of the GSV/SSV is effective, safe in the long term and well-accepted by patients. UGFS is a viable option to surgery and endovenous thermal or nonthermal ablation in the treatment of saphenous trunk incompetence (CEAP clinical grade 2-4).

2025-03-01·Antonie van Leeuwenhoek

Genomic insights into Marinospirillum alkalitolerans sp. nov., a novel PHB producing bacterium from an Indian impact crater, and an emended description of family Oceanospirillaceae

Article

作者: Sharma, Avinash ; Prabhu, Atharva ; Joshi, Amaraja ; Joseph, Neetha ; Thite, Sonia ; Godbole, Devika ; Sindhu, Dev Kant ; Yadav, Amit ; Boruah, Dibyajyoti ; Lodha, Tushar

Two Gram-stain-negative bacterial strains (MEB164^T and MEB148), were isolated from haloalkaline waters of Lonar, crater lake, India. The strains were helical, non-spore-forming and motile with polar tufts of flagella. Optimal growth occurred at 37 ℃, at pH 10 and with 3% (w/v) NaCl. 16S rRNA gene sequences of strains (MEB164^T and MEB148) demonstrated the highest similarity with Marinospirillum alkaliphilum DSM 21637^T (97.8%) followed by Marinospirillum celere DSM 18438^T (96%). The genome size of strain MEB164^T was determined to be 2.8 Mb with genomic DNA G + C contents of 53.1 mol %. ANI and dDDH values between strain MEB164^T and the most closely related type strain M. alkaliphilum DSM 21637^T were (72.3% and 21.4 ± 2.3%) while (AAI and POCP) values were (66.8 and 70.8%), respectively. Strain MEB164^T exhibited potential for polyhydroxybutyrate (PHB) production, supported by key genes involved in PHB metabolism. Genome analysis further revealed presence of various pH tolerance genes, highlighting its adaptation to Lonar Lake. The predominant cellular fatty acids were summed feature 8 (C_18:1 ω7c/C_18:1 ω6c), C_16:0 and summed feature 3 (C_16:1 ω7c/C_16:1 ω6c). The major respiratory quinone was ubiquinone-8. The prevalent polar lipids were diaminophosphatidylglycerol, phosphatidylglycerol, phosphatidylethanolamine, two unidentified amino phospholipids, three unidentified phospholipids and one unidentified lipid. Polyphasic analysis suggests that the two strains constitute a novel species within the genus Marinospirillum (family Oceanospirillaceae), proposed as Marinospirillum alkalitolerans sp. nov. The type strain is MEB164^T (= JCM 35957^T = MCC 5207^T = NCIMB 15458^T) and MEB148 (= JCM 35956 = MCC 5212 = NCIMB 15459) is an additional strain.

2025-01-06·International Journal of Systematic and Evolutionary Microbiology

Tistrella arctica sp. nov., isolated from the surface seawater of the Bering Sea and Chukchi Sea and emended description of the genus Tistrella

Article

作者: Li, Guangyu ; Lai, Qiliang ; Liu, Xiupian ; He, Ziyuan ; Zhang, Jinzhu ; Dong, Chunming ; Shao, Zongze ; Pan, Panyi ; Wang, Jianning

Two Gram-stain-negative, motile, non-spore-forming, aerobic or facultative anaerobic and short rod-shaped bacterial strains, 25B02-3T and BH-R2-4, were isolated from surface seawater collected from the Bering Sea and Chukchi Sea, respectively. The 16S rRNA gene sequences of the two strains were identical. The phylogenetic analysis of the 16S rRNA gene sequences indicated that they were related to the genus Tistrella and shared 99.6 and 98.2% sequence similarity with T. bauzanensis BZ78T and T. mobilis IAM 14872T, respectively. Both 16S rRNA gene and genome sequence-based phylogenetic analyses showed that the two strains formed a monophyletic clade within the genus Tistrella, indicating that they may represent a novel species. The digital DNA‒DNA hybridization (dDDH) values and average nucleotide identities (ANI) between the two strains were 93 and 99%, respectively, indicating that they are different strains. The dDDH and ANI values between the two strains and the type strains of the genus Tistrella were 22.4–58.3% and 81.0–95.0%, respectively. These data clearly demonstrated that the two strains represent a separate genomic species of the genus Tistrella. The principal fatty acids were Sum In Feature 8 (C18 : 1ω7c or C18 : 1ω6c), C19 : 0 cyclo ω8c, Sum In Feature 2 (C12 : 0 aldehyde or unknown 10.928) and C16 : 0. The predominant respiratory quinone was Q-10, with a minor Q-9. The polar lipids included phosphatidylethanolamine, aminolipids and phospholipids. The genomic DNA G+C contents of strains 25B02-3T and BH-R2-4 were 67.3 mol% and 67.4 mol%, respectively. On the basis of the polyphasic evidence presented in this study, the two strains represent a novel species within the genus Tistrella, for which the name Tistrella arctica sp. nov. is proposed. The type strain is 25B02-3T (=MCCC 1A07333T=KCTC 8340T).

1

项与十四烷基硫酸钠相关的新闻（医药）

2024-12-12

·上海医药

上海医药十四烷基硫酸钠注射液获得临床试验批准通知书

近日，上海医药全资子公司上海上药第一生化药业有限公司收到国家药品监督管理局核准签发的关于十四烷基硫酸钠注射液的《药物临床试验批准通知书》（通知书编号：2024LP02466、2024LP02467），将于近期启动Ⅰ期临床试验。药物名称十四烷基硫酸钠注射液剂型注射剂申请事项境内生产药品注册临床试验申报受理号 CYHL2400166、CYHL2400167 通知书编号 2024LP02466、2024LP02467 结论根据《中华人民共和国药品管理法》及有关规定，经审查，十四烷基硫酸钠注射液符合药品注册的有关要求，同意本品开展临床试验。相关信息十四烷基硫酸钠是一种硬化剂，拟用于治疗无并发症的原发性下肢浅静脉曲张、术后复发或残留的静脉曲张及简单扩张的下肢网状静脉，小静脉和蜘蛛状静脉。十四烷基硫酸钠注射后化学刺激性小，不产生剧烈疼痛，无醉酒样反应等，具有疗效确切、安全性好等优势。该项目由上药第一生化自主研发，并拥有完全知识产权，截至目前，国内尚无十四烷基硫酸钠注射液获批上市。2024年8月，该项目的临床试验申请获得国家药监局正式受理，近日，该项目获得国家药监局核准签发《药物临床试验批准通知书》，同意按照已提交的方案开展临床试验。 IQVIA数据库显示，2023年同类适应症药物的国内医院采购金额为人民币41,806万元。

临床1期申请上市

100 项与十四烷基硫酸钠相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D06882	十四烷基硫酸钠	C05BB04	DB00464

研发状态

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


AUA2022	N/A	睾丸鞘膜积液	176	sodium tetradecyl sulphate (Aspiration alone)	(鹹鑰鹽餘製衊鹽廠壓簾) = 壓鏇網遞願襯範襯壓選築壓觸範淵糧願繭夢餘 (構獵繭鹹製願築糧醖製 ) 更多	-	2022-05-01
				Ethanol sclerosed	(鹹鑰鹽餘製衊鹽廠壓簾) = 鏇憲觸簾艱齋構鹹範膚築壓觸範淵糧願繭夢餘 (構獵繭鹹製願築糧醖製 ) 更多
NCT03311269 (VICARES, CTgov)	临床2期	静脉功能不全	19	ClariVein RES+Sodium Tetradecyl Sulfate 1% Injection (ClariVein RES 1% Injection)	願鹽鹽鬱壓遞鹽膚鏇餘(鹽繭繭觸蓋積糧鏇製遞) = 糧網積顧範夢鏇鏇蓋廠獵餘鹽繭糧糧壓鑰獵衊 (築鑰網糧壓築築鹽構餘, 淵艱遞積網憲夢網鹹齋 ~ 艱觸糧網醖觸觸範蓋顧) 更多	-	2022-03-02
				ClariVein RES+Sodium Tetradecyl Sulfate 3% Injection (ClariVein RES 3% Injection)	願鹽鹽鬱壓遞鹽膚鏇餘(鹽繭繭觸蓋積糧鏇製遞) = 製壓遞網鹹製鹽壓製壓獵餘鹽繭糧糧壓鑰獵衊 (築鑰網糧壓築築鹽構餘, 鏇壓築鬱築衊膚蓋願膚 ~ 簾醖網壓蓋顧餘齋廠鬱) 更多
NCT03363633 (Dillavou, CTgov)	N/A	静脉血管疾病	12	sodium tetradecyl sulfate	鑰餘膚遞憲襯鬱鹽淵獵(鹹蓋製願艱艱網鬱觸鹹) = 選鹹鏇範齋夢範鏇鏇簾艱憲鏇壓範觸襯廠鬱夢 (淵廠網積齋積廠鏇鏇淵, 願鏇築獵糧願願構糧淵 ~ 蓋顧窪壓簾顧獵遞窪鹹) 更多	-	2018-02-23
EASI study (Pubmed \| Phlebology)	N/A	毛细血管扩张	316	Polidocanol 0.5%	(齋蓋選膚夢鬱醖壓製膚) = 壓觸衊廠憲窪選鹹簾製鹽鏇獵鏇淵醖範齋餘範 (憲鏇膚壓鏇鬱淵範築糧 )	积极	2010-06-01
				Sodium tetradecyl sulphate 1%	(齋蓋選膚夢鬱醖壓製膚) = 齋網網製鏇憲簾獵廠觸鹽鏇獵鏇淵醖範齋餘範 (憲鏇膚壓鏇鬱淵範築糧 )